| Similar Articles |
|---|
 |
The Motley Fool
August 18, 2010
Travers & Jayson |
Will Dendreon Burn You? You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big. Don't start with the science; ignore the sexy story, and look at the cold, hard cash. How does Dendreon stack up?   |
The Motley Fool
January 20, 2004
Dave Marino-Nachison |
Dendreon Calls for Cash Investors don't mind a secondary offering when it comes on the coattails of good news. |
The Motley Fool
October 19, 2009
Rich Smith |
This Just In: Upgrades and Downgrades Merriman Curhan Ford thinks Geron could as much as double off today's price, primarily in response to successful data on GRN163L, a treatment that targets cancer agent telomerase. |
The Motley Fool
January 20, 2012
Dan Caplinger |
Can Geron Recover in 2012? Let's look at this year's prospects for this company. |
The Motley Fool
November 3, 2009
Rich Smith |
This Just In: Upgrades and Downgrades Needham suspends clinical trial of buying Geron. |
The Motley Fool
May 5, 2004
Paul Elliott |
An Investor's Worst Enemy As an investor, few things assure you'll go hungry like a board of directors cutting the pie into more and more pieces and handing them out. Excessive share dilution is precisely that. |
The Motley Fool
November 15, 2011
Brian Orelli |
When Giving Up Is a Good Move in Biotech Geron calls it quits with stem cells. |
The Motley Fool
November 9, 2004
Rich Smith |
Veni Vidi Ventiv The pharma facilitator boosts revenues and profits. Were the company to rein in its dilution, it's not inconceivable that in the months to come, it might earn itself a recommendation as a Hidden Gem. |
The Motley Fool
October 31, 2008
Brian Orelli |
World's Scariest Stock: Dendreon The fear of the unknown makes investing scary, and things don't get much more unknown than the future of biotech company Dendreon. |
